Merck Canada says new drug price regulations are unconstitutional

(Reuters) – Merck Canada and a group of pharmaceutical companies are challenging the constitutionality of new regulations meant to lower patented drug prices, the company said in a statement on Friday, in a late bid to derail reforms that would hurt pharmaceutical companies’ earnings.

The Canadian government announced final regulations that give new powers to the Patented Medicine Prices Review Board (PMPRB) earlier this month, and published them in an official register on Wednesday. They go into force on July 1, 2020.

Reporting by Allison Martell in Toronto, additional reporting by Kelsey Johnson in Ottawa


READ  Researchers make strides in race to create coronavirus vaccine


Please enter your comment!
Please enter your name here